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Abstract Dopamine (DA) inhibits rodent proximal tubule
Na+,K+-ATPase via stimulation of protein kinase C (PKC).
However, direct stimulation of PKC by phorbol 12-myristate 13-
acetate (PMA) results in increased Na+,K+-ATPase. LY333531,
a specific inhibitor of the PKC-L isoform, prevents PMA-
dependent activation of Na+,K+-ATPase, but has no effect on
DA inhibition of this activity. A similar result was obtained with
a PKC-L inhibitor peptide. Concentrations of staurosporine, that
inhibits PKC-j, prevent DA-dependent inhibition of Na+,K+-
ATPase and a similar effect was obtained with a PKC-j inhibitor
peptide. Thus, PMA-dependent stimulation of Na+,K+-ATPase
is mediated by activation of PKC-L, whereas inhibition by DA
requires activation of PKC-j.
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1. Introduction
The molecular mechanism by which hormone receptors
coupled to stimulation of protein kinase C (PKC) regulate
sodium re-absorption in renal proximal convoluted tubules
is not well understood [1]. The Na,K-ATPase, located with-
in the basolateral membrane of tubular epithelial cells, main-
tains a transmembrane concentration gradient for sodium,
ensuring the net re-absorption of this cation [2,3]. It has
been suggested that hormonal short term regulation of
Na,K-ATPase activity may contribute to the ability of
the kidney to adjust sodium re-absorption [1,4].
In opossum kidney (OK) cells, a cell culture model of prox-
imal tubule epithelia [5,6], dopamine (DA) inhibits and phor-
bol esters stimulate Na,K-ATPase activity [7^10]. DA-de-
pendent inhibition and phorbol 12-myristate 13-acetate
(PMA)-dependent stimulation of Na,K-ATPase activity
are mediated by PKC and phosphorylation of serine residues
within the Na,K-ATPase K-subunit NH2-terminus [7^11].
DA treatment of OK cells results in phosphorylation of K-
subunit Ser-18 and this is essential for inhibition of Na,K-
ATPase activity [9]. Upon phosphorylation, Na,K-ATPase
molecules are internalized and this results in a lower Na,K-
ATPase capacity at the cell membrane [9,10]. On the other
hand, PMA treatment of OK cells results in phosphorylation
of both Ser-11 and Ser-18 of the K-subunit and the presence
of either of these amino acids is essential for PMA-dependent
activation of Na,K-ATPase [11]. Increased Na,K-ATP-
ase activity may be the consequence of translocation of
Na,K-ATPase molecules from intracellular compartments
to the plasma membrane as described in other transporting
epithelia [12]. The fact that both activation and inhibition of
Na,K-ATPase activity are mediated by stimulation of PKC
suggests that two di¡erent isoforms of this enzyme may be
responsible for these processes. In this report, we present evi-
dence that PKC-L and PKC-j are the isoforms responsible for
the opposing e¡ects of DA and phorbol esters on proximal
tubule Na,K-ATPase activity.
2. Materials and methods
2.1. Materials
Cell culture supplies were purchased from Life Sciences Technolo-
gies (Grand Island, NY, USA) and Hyclone Laboratories (Logan,
UT, USA). Molecular biology reagents were from New England Bio-
labs (Beverly, MA, USA), Promega (Madison, WI, USA), Stratagene
(La Jolla, CA, USA) and Sigma Chemical (St. Louis, MO, USA). DA
(3-hydroxytyramine), monensin sodium salt, PMA and staurosporine
(antibiotic AM-2282) were obtained from Sigma Chemical. LY333531
(mesylate monohydrate) was a kind gift from Eli Lilly (Indianapolis,
IN, USA). [86Rb]RbCl was obtained from DuPont NEN Life
Science Products (Boston, MA, USA). Peptide inhibitors of PKC
isoforms were a kind gift of Dr Daria Mochly-Rosen, Stanford Uni-
versity, School of Medicine.
2.2. Cell culture and transfection
OK cells were maintained at 37‡C (10% CO2) in Dulbecco’s modi-
¢ed Eagle medium with 10% calf serum and antibiotics (DMEM-10).
Transfection of OK cells with rodent K1-cDNA was performed as
previously described [7]. Selection for cells expressing the highest level
of rodent K-subunit was achieved by exposing them to a medium
containing 3 WM ouabain. Resistant colonies were expanded and
maintained in DMEM-10 containing 3 WM ouabain. Experiments
were performed with a mix of at least 20 independent clones for
each cell line. The Na,K-ATPase of mock-transfected cells (vector
alone, vector plus liposomes or liposomes alone) had the same activity
and sensitivity to ouabain as non-transfected host cells. The endoge-
nous Na,K-ATPase activity was inhibited by growing the cells and
performing the experiments in the presence of 3 WM ouabain. Accord-
ingly, any Na,K-ATPase activity that we observed must originate
with the Na,K-ATPases containing the introduced rodent K-sub-
unit.
2.3. Determination of Rb+-transport
Measurements of Na,K-ATPase-mediated Rb-transport were
performed as described [7]. To determine the e¡ect of DA on Rb-
transport, cells were incubated with 30 WM monensin for 10 min as
described by Seri et al. [13]. Cells were incubated with 0.1 WM PMA
(10 min) or 0.1 WM DA (5 min) before assaying.
2.4. Introduction of peptides into OK cells
To facilitate the delivery of peptides into cells without a¡ecting the
long-term cell viability, the permeabilization protocol described by
Johnson et al. [14] was followed. Brie£y, cells were slowly brought
down in temperature with two sequential 2 min PBS incubations, ¢rst
at room temperature and the second with chilled PBS. The cells were
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then incubated on ice with freshly prepared permeabilization bu¡er
(20 mM HEPES, 10 mM EGTA, 140 mM KCl, 50 Wg/ml saponin,
5 mM NaN3 and 5 mM oxalic acid dipotassium salt, pH 7.4) con-
taining the desired peptide for 10 min. The cells were then gently
washed for four times with chilled PBS and incubated for 20 min
with chilled PBS on ice. The chilled PBS was discarded and the cells
were incubated at room temperature for 2 min in room temperature
PBS. Finally, the cells were transferred to assay medium.
2.5. Treatment with PKC inhibitors
The cells were incubated at room temperature with the inhibitors of
PKC, LY333531 or staurosporine, for 30 min at di¡erent concentra-
tions before the assay of Rb-transport. We used 1% of DMSO to
solubilize LY333531 and found that the solvent alone had no e¡ect on
the Na,K-ATPase activity of the cells.
2.6. Statistical analysis
Comparison of the data between groups was performed by Stu-
dent’s t-test for unpaired data.
3. Result and discussion
In proximal tubules, angiotensin II and K1-adrenergic re-
ceptors stimulation increases sodium re-absorption in a proc-
ess mediated by PKC [1,4,15^17]. On the contrary, DA stim-
ulation of D1 receptor subtype leads to a reduced sodium re-
absorption and this process also requires activation of PKC
[18^21]. We have previously proposed that these e¡ects could
be mediated, at least in part, by regulation of renal tubules
Na,K-ATPase activity [1,7]. Consistent with this hypothe-
sis, the opposite e¡ects of angiotensin II/epinephrine and DA
in proximal tubule sodium re-absorption correlate with the
activation (phorbol ester) and inhibition (DA) of Na,K-
ATPase activity previously described in OK cells [7^10].
The PMA stimulation and DA inhibition of Na,K-ATP-
ase-mediated Rb-transport are illustrated in Fig. 1. These
e¡ects are mediated by PKC-dependent phosphorylation of
Ser residues located at the Na,K-ATPase K-subunit NH2-
terminus [7^10]. Therefore, it is likely that the di¡erential
e¡ect of PMA and DA on sodium transport may be due to
regulation of Na,K-ATPase activity by stimulation of dif-
ferent PKC isoforms. We have determined using immunoblot
analysis that OK cells express all PKC isoforms except Q (data
not shown). The appropriate experimental design to determine
whether the opposite e¡ects of PMA and DA are mediated by
activation of di¡erent isoforms of PKC would be to use iso-
form-speci¢c inhibitors of PKC. However, few of these inhib-
itors have been described and most of them are not commer-
cially available [22,23]. Recently, the synthesis of a novel and
highly speci¢c inhibitor of PKC-L1/L2, LY333531, was re-
ported [24]. LY333531 inhibits PKC-L1/L2 with a half-maxi-
mal inhibitory constant (IC50) of approximately 5 nM. This
concentration is 50-fold lower than the concentration required
to inhibit other PKC isoenzymes [24]. Furthermore, it has
been shown that LY333531 is highly speci¢c and e¡ective
both in vitro and in vivo [24,25].
To study the involvement of di¡erent PKC isoforms, we
determined the e¡ect of PMA and DA on Rb-transport in
cells that have been treated with LY333531 and other PKC
isoform-speci¢c inhibitors. To allow comparison of the results
with those reported in our previous publications, the experi-
ments were performed in OK cells transfected with the rodent
Na,K-ATPase K1-cDNA. However, PMA-dependent acti-
vation and DA-dependent inhibition of Na,K-ATPase ac-
tivity also occur in non-transfected OK cells. As illustrated in
Fig. 2, 10 nM LY333531 almost totally impaired the stimula-
tory e¡ect of PMA on Rb-transport. This result strongly
suggests that PKC-L1/L2 isozymes may be responsible for
the PMA e¡ect. Low concentrations of staurosporine (60
nM) were su⁄cient to prevent the stimulatory e¡ect of
PMA on Na,K-ATPase activity (Fig. 3). However,
LY333531 (even at a high concentration) could not prevent
the inhibitory e¡ect of DA on Na,K-ATPase (data not
shown). It is possible that concentrations of LY333531 su⁄-
cient to inhibit PKC-j could not be accumulated into the
cells.
The fact that PMA did not produce an inhibition of the
Na,K-ATPase activity as DA did suggested that DA may
be activating a member of the atypical PKC isozymes which
are insensitive to phorbol esters [22,26,27]. It has previously
been suggested that PKC-j may be involved in regulation of
Na,K-ATPase activity [28,29]. To test whether PKC-j in-
deed mediates the e¡ects of DA on Na,K-ATPase activity,
we initially studied the e¡ect of high concentrations of stauro-
sporine. Unlike LY333531, staurosporine does not discrim-
inate between the PKC isozymes [24]. Most PKC isoforms are
inhibited by this compound in the nM range, except PKC-j
which requires Wmol concentrations. As anticipated, 10 WM
staurosporine was necessary to prevent the inhibitory e¡ect of
DA on Na,K-ATPase activity (Fig. 4). Thus, results with
PKC inhibitors LY333531 and staurosporine support the hy-
pothesis that PMA-dependent activation and DA-dependent
Fig. 1. E¡ect of DA and PMA on the Na,K-ATPase-mediated
Rb-transport.
Fig. 2. E¡ect of various concentrations of LY333531 on PMA-de-
pendent activation of Rb-transport.
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inhibition of Na,K-ATPase activity are mediated by PKC-
L and PKC-j, respectively.
It is known that when PKCs are activated by lipid-derived
second messengers, they translocate from the cytosol to the
cell membrane. Recently, Dr Mochly-Rosen and collaborators
[26,30] have demonstrated that most inactive PKC isozymes
are localized to subcellular structures and, upon activation,
translocate to new distinct intracellular sites and this is due
to their binding to speci¢c anchoring molecules. The anchor-
ing proteins for activated PKC isozymes were termed recep-
tors for activated C-kinase (RACKs). It is then likely that the
unique cellular functions of PKCs are determined by the bind-
ing of isozymes to speci¢c anchoring molecules in close prox-
imity to particular subsets of substrates and away from others
[26,30]. Accordingly, peptides that mimic either the PKC
binding site on RACKs or the RACK binding site on PKC
are translocation inhibitors of PKC that block the function of
the enzyme in vivo [26,30]. Using peptides kindly provided by
Dr Mochly-Rosen to inhibit PKC-L and PKC-j, we employed
the same strategy to investigate whether these isoforms indeed
mediate the e¡ects of PMA and DA. The peptides were in-
ternalized into OK cells following a protocol previously de-
veloped by these investigators [30]. As illustrated in Table 1,
the PKC-L-derived inhibitor peptide C2-4 (SLNPEWNET)
prevents the stimulatory e¡ect of PMA on Na,K-ATPase
activity and has no e¡ect on the inhibitory action elicited by
DA. A scrambled peptide (WNPESLNTE) has no e¡ect on
either the PMA or DA e¡ect. On the contrary, a peptide
derived from the pseudosubstrate region of PKC-j isozyme
prevents the inhibitory e¡ect of DA on Na,K-ATPase ac-
tivity but does not a¡ect the stimulatory action of PMA.
These data correlate very well with the results obtained with
LY333531 (Fig. 2) and staurosporine (Figs. 3 and 4). The fact
that control cells treated with the permeabilizing protocol to
introduce the scrambled peptide or none (mock-treated) pre-
sented the same level of Rb-transport as non-treated cells
indicates that the permeabilizing protocol is not producing
any deleterious e¡ects that may a¡ect the basal Na,K-ATP-
ase or its regulation. Our novel ¢nding that PKC-j is involved
in DA-dependent inhibition of Na,K-ATPase activity is
consistent with the previous published result that wortmannin
and LY294009 also prevent this inhibition [9,10,31] since these
are inhibitors of PI3K which has been described to be in-
volved in the activation of PKC-j [32,33].
The present results help to understand the apparent contra-
diction in previously published reports concerning the di¡er-
ent e¡ects of PKC activation on Na,K-ATPase activity.
Depending on the tissue studied and the experimental condi-
tions, stimulation of PKC could lead to inhibition [20,34^37]
or to activation [7,8,16,35,37^44] of Na,K-ATPase activity.
It is therefore likely that these e¡ects are due to activation of
di¡erent PKC isoforms being able to phosphorylate Na,K-
ATPase in di¡erent tissues. This conclusion is further sup-
ported by the following observation. Although stimulation
of endogenous Xenopus laevis oocytes PKC produced inhib-
ition of Na,K-ATPase-mediated Rb-transport, microin-
jection into oocytes of rodent PKC led to increased Rb-
transport [37]. Furthermore, rat PKC inhibited the Na,K-
ATPase-mediated Rb-transport of X. laevis oocytes trans-
fected with rodent K1 but stimulated the endogenous activity
[37]. Taken together, these data suggest that stimulation of
hormone receptors or direct stimulation of PKC by phorbol
esters may activate di¡erent PKC isoforms in di¡erent tissues.
Thus, whether activation, inhibition or no e¡ect on the activ-
ity of Na,K-ATPase is observed could depend on the co-
incident expression of a speci¢c Na,K-ATPase K-isoform
with a particular isoform of PKC.
In conclusion, phorbol ester and dopaminergic e¡ects on
proximal tubule Na,K-ATPase may be mediated by PKC-
L and PKC-j, respectively. Although we have previously sug-
gested this [7^9], the present ¢ndings are the ¢rst experimental
evidence that activation and inhibition of the Na,K-AT-
Pase produced by phorbol esters or DA are the consequence
of di¡erent PKC isoforms.
Fig. 3. E¡ect of various concentrations of staurosporine on PMA-
dependent activation of Rb-transport.
Fig. 4. E¡ect of various concentrations of staurosporine on DA-de-
pendent inhibition of Rb-transport.
Table 1
E¡ect of PKC isozyme peptide inhibitors on PMA stimulation and
DA inhibition of Rb-transport
Peptide inhibitors Rb-transport (nmol/mg protein/min)
Control PMA DA
None 10.1 þ 1.3 17.4 þ 1.7 5.7 þ 0.6
LC2-4 9.9 þ 1.0 11.2 þ 1.5 5.9 þ 1.1
Scrambled 10.4 þ 1.1 18.3 þ 2.2 6.1 þ 0.9
PKC-j pseudo 9.7 þ 1.0 16.9 þ 1.3 9.1 þ 1.2
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